CVS Health® is committed to providing high-quality, cost-effective medications, including biosimilar drugs. These biosimilars are essential for patients with chronic and severe conditions, as they offer a more affordable alternative for treatment. From cancer to diabetes, biosimilars have the potential to significantly reduce drug costs in today’s healthcare system.
In a recent report, Dr. Sree Chaguturu, EVP and CMO of CVS Health, explored the benefits of biosimilar drugs in making treatments more accessible. The report also highlighted Cordavis™, a CVS Health subsidiary that specializes in producing top-notch biosimilars. Through their efforts, Cordavis™ is improving patient access to these life-changing medications and driving innovation in the field of healthcare.
If you want to learn more about the impact of biosimilar drugs and how they are revolutionizing the healthcare industry, you can access the full report (PDF) on our website.
